What is the current Price Target for the Monopar Therapeutics Inc stock?

The average Monopar Therapeutics Inc target price is $111.18. This is 44.04% higher than the current stock price. The highest price target is 76.85%, the lowest is 21.69%. 15 Analysts have issued a price target Monopar Therapeutics Inc 2026 .

How high will the Monopar Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Monopar Therapeutics Inc stock will rise. The performance of stocks, including the Monopar Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Monopar Therapeutics Inc stock today?

The performance of Monopar Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Monopar Therapeutics Inc stock fall?

The decline in Monopar Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Monopar Therapeutics Inc Forecast, price target & analysts

$77.19

1.64% yesterday

Nasdaq, Dec 03, 10:00 pm CET

ISIN

US61023L1089

Symbol

MNPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monopar Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Monopar Therapeutics Inc Classifications & Recommendation:

Buy

94%

Hold

Monopar Therapeutics Inc Price Target

Target Price	$111.18
Price	$77.19
Potential	44.04% register free of charge
Number of Estimates	15

	15 Analysts have issued a price target Monopar Therapeutics Inc 2026 . The average Monopar Therapeutics Inc target price is $111.18. This is 44.04% register free of charge higher than the current stock price. The highest price target is $136.50 76.85% register free of charge , the lowest is $93.93 21.69% register free of charge .
	A rating was issued by 18 analysts: 17 Analysts recommend Monopar Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Monopar Therapeutics Inc stock has an average upside potential 2026 of 44.04% register free of charge . Most analysts recommend the Monopar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-4.22	-1.72
	38.82%	59.24%
P/E		negative

14 Analysts have issued a Monopar Therapeutics Inc forecast for earnings per share. The average Monopar Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-4.22	38.82%
2025	$-1.72 59.24% Unlock
2026	$-3.70 115.12% Unlock
2027	$-3.27 11.62% Unlock
2028	$-2.68 18.04% Unlock
2029	$-0.96 64.18% Unlock
2030	$3.54 468.75% Unlock
2031	$10.83 205.93% Unlock
2032	$17.47 61.31% Unlock

Current	-30.74	149.73%
2025	-44.02 43.18% Unlock
2026	-20.50 53.43% Unlock
2027	-23.25 13.41% Unlock
2028	-28.33 21.85% Unlock
2029	-78.87 178.40% Unlock
2030	21.44 127.18% Unlock
2031	7.01 67.30% Unlock
2032	4.35 37.95% Unlock

Monopar Therapeutics Inc...

Current Monopar Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Raymond James	Locked ➜ Locked	Locked	Nov 14 2025
Chardan Capital	Locked ➜ Locked	Locked	Nov 13 2025
Leerink Partners	Locked ➜ Locked	Locked	Nov 10 2025
Chardan Capital	Locked ➜ Locked	Locked	Nov 09 2025
Barclays	Locked ➜ Locked	Locked	Oct 13 2025
Raymond James	Locked ➜ Locked	Locked	Oct 06 2025
Oppenheimer	Locked ➜ Locked	Locked	Oct 02 2025

Analyst Rating	Date
Locked Raymond James: Locked ➜ Locked	Nov 14 2025
Locked Chardan Capital: Locked ➜ Locked	Nov 13 2025
Locked Leerink Partners: Locked ➜ Locked	Nov 10 2025
Locked Chardan Capital: Locked ➜ Locked	Nov 09 2025
Locked Barclays: Locked ➜ Locked	Oct 13 2025
Locked Raymond James: Locked ➜ Locked	Oct 06 2025
Locked Oppenheimer: Locked ➜ Locked	Oct 02 2025

Discover more stocks with a high price target

Coinbase Global, Inc. 47.34%

BioNTech SE - ADR 46.05%

Deutsche Telekom 42.50%

BYD 41.35%

Novo Nordisk 37.45%

TUI 37.00%

Meta Platforms (Facebook) 35.55%

Adyen 34.62%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now